Gasterointestinal endoscopy ward, Amir Alam hospital, Tehran university of medical sciences
Tehran, Tehran Province, Iran
NCT Number: NCT01269788
Gastro-esophageal reflux disease (GERD) is highly prevalent, affecting up to 20% of the adult population in North America. Up to 70% of GERD patients have non-erosive reflux disease (NERD), a term used to describe symptoms suggestive of GERD in patients with no endoscopic evidence of erosive esophagitis. NERD represents a heterogeneous group of patients whom are sub classified according to 24 hours-PH monitoring results and also symptom-acid association analysis(Symptom Index,SI).
Treatment of NERD can be a challenge for clinicians. According to the many studies , the pooled rate for symptomatic response after a period of proton pomp inhibitor(PPIs)therapy as the most frequently used drug, in NERD patients is lower than for erosive esophagitis patients. It is also shown that acid exposure is much lower in NERD patients than those with erosive esophagitis and NERD patients are less likely to exhibit a strong association between heartburn symptoms and acid reflux events than patients with erosive oesophagitis.
Furthermore, beside the high economic burden, there are concerns about the adverse effects of long time administration of PPIs.
Several hypothesis has been proposed to describe low response rate of NERD patients to PPIs. One of the most acceptable theories is that patients with anxiety or depression and psychological problems are at an increased risk of developing reflux symptoms. On the other hand, pain modulators such as sertraline, a selective serotonin reuptake inhibitor(SSRI), and other antidepressants have been shown to improve symptoms in patients with functional gastrointestinal disorders like non cardiac chest pain.
According to the above-mentioned tips, the investigators hypothesize that antidepressants like fluoxetine, as an SSRI, may have beneficial effects in improving symptoms of NERD patients.
The purpose of this study is to compare the effect of omeprazole with fluoxetine and placebo for treatment of NERD patients and its subgroups who all experience reflux symptoms and have normal endoscopic findings.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 2 / Phase 3
Tehran, Tehran Province, Iran
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
20 mg , oral , daily 30 mins before breakfast, for 6 weeks
20 mg , oral , daily 30 mins before breakfast, for 6 weeks
oral , daily 30 mins before breakfast, for 6 weeks
Time frame: 6 weeks
symptom severity at beginning and 6 weeks after the study ,assessed by the standard questionnaire
Time frame: 6 weeks
symptom severity reported by the patient in daily diary
Time frame: 6 weeks
percentage of 24-h heartburn-free days (days with neither daytime nor nighttime heartburn) during treatment assessed by daily diary
Tehran University of Medical Sciences
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05890001
Deglutition Disorders, Digestive System Diseases
Huntsville, Alabama, United States
View Trial DetailsNCT07041060
Deglutition Disorders, Digestive System Diseases
Bologna, Italy
View Trial DetailsNCT05587322
Deglutition Disorders, Digestive System Diseases
Huntsville, Alabama, United States
View Trial DetailsNCT02081404
Deglutition Disorders, Digestive System Diseases
Kansas City, Missouri, United States
View Trial Details